Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names

Acthib, Pentacel

Generic Name

Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

DrugBank Accession Number

DB10076

Background

Haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine for intramuscular injection used in the prevention of invasive disease caused by Haemophilus influenzae type b. H. influenzae is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis. The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid ¹. The toxoid antigen is purified and toxin-inactivated.

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Vaccines
Inactivated / Toxoid / Conjugate

Synonyms

Haemophilus influenzae type B strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Invasive Infection caused by Haemophilus Influenzae Type B

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
ActHIB	Injection, powder, lyophilized, for solution; Kit	10 ug/0.5mL	Intramuscular	Sanofi Pasteur Inc.	1993-03-30	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Act-hib	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg)	Kit; Powder, for solution	Intramuscular	Sanofi Pasteur Limited	1992-12-31	Not applicable
Infanrix-hexa	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (8 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (10 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 lf / 0.5 mL) + Hepatitis B Vaccine (Recombinant) (10 mcg / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL)	Suspension	Intramuscular	Glaxosmithkline Inc	2008-12-04	Not applicable
Menhibrix	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)	Kit	Intramuscular	GlaxoSmithKline Biologicals SA	2013-09-03	2017-09-17
Menhibrix	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 ug/0.5mL)	Injection, powder, lyophilized, for solution	Intramuscular	GlaxoSmithKline Biologicals SA	2013-09-03	2013-11-27
Pediacel	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 mcg / 0.5 mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (3 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (20 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 lf / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL)	Suspension	Intramuscular	Sanofi Pasteur Limited	2007-10-04	Not applicable
Pentacel	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL)	Injection; Injection, suspension; Kit	Intramuscular	Sanofi Pasteur Inc.	2008-06-20	Not applicable
Pentacel	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL)	Injection; Injection, suspension; Kit	Intramuscular	Sanofi Pasteur Inc.	2008-06-20	Not applicable
PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (10 mcg/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 mcg/0.5ml) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)	Injection, powder, for suspension	Intramuscular	SANOFİ PASTEUR AŞI TİC. A.Ş.	2020-08-14	Not applicable
Prohibit Inj Vaccine	Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (25 mcg / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (23 mcg / 0.5 mL)	Liquid	Intramuscular	Aventis Pasteur Limited	1988-12-31	2000-05-27

Chemical Identifiers

UNII: FLV5I5W26R
CAS number: Not Available

References

General References

Dailymed Label: ACTHIB- haemophilus influenzae type b strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen [Link]

External Links

PubChem Substance: 347910467
RxNav: 1300464

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Prevention	Acute Lymphoblastic Leukaemias (ALL)	1
4	Completed	Prevention	BCG Infection / Immune Responses / Vaccine Reaction	1
4	Completed	Prevention	Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus	1
4	Completed	Treatment	Pain	1
3	Active Not Recruiting	Prevention	Meningococcal Infection (Healthy Volunteers)	1
3	Completed	Prevention	Acellular Pertussis / Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B	1
3	Completed	Prevention	Bacterial Infections / Neisseria Meningitidis / Viral Disease	1
3	Completed	Prevention	Bacterial Infections / Viral Disease	2
3	Completed	Prevention	Diphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus	1
3	Completed	Prevention	Diphtheria / Haemophilus Influenzae Serotype b (Hib) / Pertussis / Poliomyelitis / Tetanus	4

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Kit; powder, for solution	Intramuscular
Injection, powder, for solution	Intramuscular	10 µg/0.5mL
Injection, powder, lyophilized, for solution; kit	Intramuscular	10 ug/0.5mL
Injection, powder, lyophilized, for solution	Intramuscular
Kit	Intramuscular
Suspension	Intramuscular
Injection; injection, suspension; kit	Intramuscular
Injection, powder, for suspension	Intramuscular
Liquid	Intramuscular
Injection, suspension	Intramuscular

Prices

Not Available

Patents

Not Available

Properties

State: Not Available
Experimental Properties: Not Available

Drug created at November 30, 2015 21:23 / Updated at November 28, 2021 16:22

Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

Identification

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties